Analysis and Consideration on Potential Risk of Fat-soluble Vitamin Injections

Abstract

Abstract: Objective To investigate the potential risks of fat-soluble vitamin injections so as to promote rational use of these products in clinical practice. Methods The valid data of fat-soluble vitamin injections were retrieved from the database of National Center for Adverse Drug Reaction Monitoring and clinical retrospective study, the clinical application characteristics and potential risks were analyzed. Results Fat-soluble vitamin injections are widely used in clinic, and the proportion of serious adverse reaction has shown an upward trend. Additionally, unreasonable and irregular use is common, which may increase the risk of adverse reactions in patients. Conclusion Fat-soluble vitamin injections should be used in accordance with indications. Meanwhile, close attention should be paid to the risk of serious allergic reactions, especially anaphylactic shock.

Key words: fat-soluble vitamin injections, allergic reaction, adverse drug reaction

CLC Number:

R994.11

XU Xianxing, YANG Jingwen, WU Guizhi, XIE Yanjun, CUI Xiaokang, XU LIli. Analysis and Consideration on Potential Risk of Fat-soluble Vitamin Injections[J]. Chinese Journal of Pharmacovigilance, 2018, 15(10): 600-602.

References

[1] CFDA.药品不良反应信息通报(第43期) 警惕维生素K1注射液的严重过敏反应[EB/OL]. (2011-12-26) [2018-08-27]. http://samr.cfda.gov.cn/WS01/CL1989/67960.htmL.
[2] 王莹,马瑶. 常见药用辅料引起的不良反应案例概述[J]. 中国医药指南,2013,11(23):380-382.
[3] 谢晓燕. 44 例转化糖注射剂不良反应/事件分析[J]. 中国药物评价,2015,32(6):352-355.
[4] 张俊芳,王映辉,蓝美群.果糖类制剂的临床应用与不良反应综述[J]. 药物流行病学杂志,2011,20(11):606-608.
[5] 许先兴,杨静文,吴桂芝,等. 含木糖醇注射剂临床应用现状及潜在风险分析[J].中国药物警戒,2017, 14(11): 680-682.
[6] 范静,李相成,李飞,等.注射用脂溶性维生素(Ⅱ)/水溶性维生素与常用电解质配伍的稳定性考察[J].中国药房,2017,28(11):1478-1482.
[7] 吴勇. 188 例门冬氨酸钾镁注射液不良反应/事件分析报告[J]. 中国药物评价, 2013,30(1):44-48.
[8] CFDA.药品不良反应信息通报(第50期)警惕门冬氨酸钾镁注射剂的严重过敏反应[EB/OL]. (2012-09-19) [2018-08-27]. http://samr.cfda.gov.cn/WS01/CL1989/74984.htmL.
[9] 曾婷. 丙氨酰谷氨酰胺不合理使用引发的不良反应情况分析[J]. 临床合理用药, 2017, 10(4C): 39-41.
[10] Hamishehkar H, Ranjdoost F, Asgharian P,et al.Vitamins, Are They Safe?[J]. Adv Pharm Bull, 2016, 6(4): 467-477.
[11] 谢华,袁海玲,陈玉芳,等. 含辅料注射剂的临床合理用药[J]. 中国现代应用药学,2016,33(4):488-492.
[12] 解家玲,张芙蓉. 脂溶性维生素的合理应用[J]. 中国医疗前沿, 2012,7(12): 71-72.
[13] 谢彦军,吴世福,田月洁,等. 491 例注射用脂溶性维生素严重不良反应分析[J]. 中国药物警戒, 2018,15(3): 176-180.
[14] CFDA.国家食药监总局决定修订复方脂溶性维生素注射剂说明书[EB/OL]. (2017-12-01) [2018-08-27].http://samr.cfda.gov.cn/WS01/CL1747/218058.htmL.

[1]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[2]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[3]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[4]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[5]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[6]	LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong. One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212.
[7]	CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin. One case of interstitial pneumonia caused by serplulimab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215.
[8]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[9]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[10]	JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
[11]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[12]	LIU Saiyue, LYU Xiaoqin, ZHOU Yun. Key points of investigation and report of suspected death of adverse drug reaction [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
[13]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[14]	PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu. Exploring the significance of collecting patient reports based on international pharmacovigilance experience [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.
[15]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.